Ads
related to: clinical research analyst
Search results
Q2 2024 Agilent Technologies Inc Earnings Call
Thomson Reuters StreetEvents via Yahoo Finance· 16 hours agoNASD declined low teens as expected, driven by more clinical products being produced this year versus Q2 of last year. Europe was a bright spot for DGG, growing low single ...
TD Cowen Begins Coverage on Fortrea (NASDAQ:FTRE)
ETF DAILY NEWS· 2 days agoEquities researchers at TD Cowen initiated coverage on shares of Fortrea (NASDAQ:FTRE – Get Free Report) in a research note issued to investors on Wednesday ...
Research Analysts Issue Forecasts for Alkermes plc’s Q3 2024 Earnings (NASDAQ:ALKS)
ETF DAILY NEWS· 3 days agoAlkermes plc (NASDAQ:ALKS – Free Report) – Equities research analysts at Zacks Research increased their Q3 2024 earnings per share (EPS ...
Analysts Set Avidity Biosciences, Inc. (NASDAQ:RNA) PT at $41.33
ETF DAILY NEWS· 6 days agoAvidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) has received an average rating of “Buy” from the six brokerages that are presently covering the stock, Marketbeat Ratings reports. Six ...
Cancer Biotech Stocks Are on the Move Ahead of a Big Event. What to Know.
Barrons.com· 6 days agoThe American Society of Clinical Oncology is set to gather on May 31 in Chicago for its annual...
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar...
Zacks via Yahoo Finance· 7 days agoEvery day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and...
Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 11 hours agoResearch and development expenses amounted to $227.7 million, down 2.7% year over year. This...
Earnings call: Cellectis reports an additional investment of $140 million from AstraZeneca By...
Investing.com· 7 hours agoThe company highlighted a significant additional equity investment of $140 million from AstraZeneca...
Cell therapy reckoning: Pivot to autoimmune leaves unmet need in oncology
FierceBiotech· 13 hours agoThis story is part 2 in a four-part series about cell therapy created by the Fierce Biotech team....
BenevolentAI S.A. (AMS:BAI) Is Expected To Breakeven In The Near Future
Simply Wall St. via Yahoo Finance· 16 hours agoHas the future growth potential already been factored into the price? The intrinsic value...
